Angiotensin II Induces Interleukin-1β–Mediated Islet Inflammation and β-Cell Dysfunction Independently of Vasoconstrictive Effects
- 28 October 2014
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 64 (4) , 1273-1283
Abstract
Pathological activation of the renin-angiotensin system (RAS) is associated with the metabolic syndrome, and the new onset of type 2 diabetes can be delayed by RAS inhibition. In animal models of type 2 diabetes, inhibition of the RAS improves insulin secretion. However, the direct effects of angiotensin II on islet function and underlying mechanisms independent of changes in blood pressure remain unclear. Here we show that exposure of human and mouse islets to angiotensin II induces interleukin (IL)-1–dependent expression of IL-6 and MCP-1, enhances β-cell apoptosis, and impairs mitochondrial function and insulin secretion. In vivo, mice fed a high-fat diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glucose-stimulated insulin secretion and deteriorated glucose tolerance. Application of an anti–IL-1β antibody reduced the deleterious effects of angiotensin II on islet inflammation, restored insulin secretion, and improved glycemia. We conclude that angiotensin II leads to islet dysfunction via induction of inflammation and independent of vasoconstriction. Our findings reveal a novel role for the RAS and an additional rationale for the treatment of type 2 diabetic patients with an IL-1β antagonist.Keywords
This publication has 50 references indexed in Scilit:
- Renin-Angiotensin System Blockers Protect Pancreatic Islets against Diet-Induced Obesity and Insulin Resistance in MicePLOS ONE, 2013
- Effects of renin-angiotensin system blockade on islet function in diabetic ratsJournal of Endocrinological Investigation, 2010
- Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II–Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor DownregulationCirculation Research, 2008
- Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function and morphology in db/db miceBiochemical and Biophysical Research Communications, 2006
- Angiotensin II Type 1 Receptor Blockade Improves β-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 DiabetesDiabetes, 2006
- Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 DiabetesJACC, 2005
- Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetesJournal Of Hypertension, 2005
- Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF RatDiabetes, 2004
- Preventing Type II Diabetes MellitusThe Journal of Clinical Pharmacology, 2004
- Increased Adipose Angiotensinogen Gene Expression in Human ObesityObesity Research, 2000